PDF(Pubmed)
Abstract：
BACKGROUND: Hepatocellular carcinoma is a highly lethal tumor worldwide, and China has a correspondingly high incidence and mortality rate. For patients with unresectable hepatocellular carcinoma, the prognosis is often poor. The objective of this retrospective study was to investigate the effects of conversion therapies on these patients.
METHODS: The study included patients between the ages of 18 and 75 who were initially diagnosed with unresectable hepatocellular carcinoma and received conversion therapy. After completing surgery, the patients underwent pathological diagnosis, which showed complete necrosis. The study was conducted retrospectively at the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2019 to December 2021. The main objectives of the study were to evaluate the overall survival and recurrence-free survival.
RESULTS: A total of 60 patients who met the inclusion criteria were enrolled. The median age of the patients was 56.6 ± 9.5 years, and 85% of them were male. The one-year overall survival rate (OS) was 98.3%, and the three-year OS was 95.6%. The one-year recurrence-free survival rate (RFS) was 81.1%, and the three-year RFS was 71.4%. In subgroup analysis, there was no statistically significant difference in RFS between patients with BCLC stages 0-A and BCLC stages B-C (p = 0.296). Additionally, there was no statistically significant difference in RFS between patients who received postoperative new adjuvant therapy and those who did not (p = 0.324).
CONCLUSIONS: Conversion therapy followed by surgical resection could be a promising treatment for patients with initially unresectable hepatocellular carcinoma, and the prognosis is good with a pathological complete response.
METHODS: The study included patients between the ages of 18 and 75 who were initially diagnosed with unresectable hepatocellular carcinoma and received conversion therapy. After completing surgery, the patients underwent pathological diagnosis, which showed complete necrosis. The study was conducted retrospectively at the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2019 to December 2021. The main objectives of the study were to evaluate the overall survival and recurrence-free survival.
RESULTS: A total of 60 patients who met the inclusion criteria were enrolled. The median age of the patients was 56.6 ± 9.5 years, and 85% of them were male. The one-year overall survival rate (OS) was 98.3%, and the three-year OS was 95.6%. The one-year recurrence-free survival rate (RFS) was 81.1%, and the three-year RFS was 71.4%. In subgroup analysis, there was no statistically significant difference in RFS between patients with BCLC stages 0-A and BCLC stages B-C (p = 0.296). Additionally, there was no statistically significant difference in RFS between patients who received postoperative new adjuvant therapy and those who did not (p = 0.324).
CONCLUSIONS: Conversion therapy followed by surgical resection could be a promising treatment for patients with initially unresectable hepatocellular carcinoma, and the prognosis is good with a pathological complete response.
摘要：
背景：肝细胞癌是世界范围内的高致死性肿瘤，而中国的发病率和死亡率也相应较高。对于不可切除的肝细胞癌患者，预后往往较差。这项回顾性研究的目的是研究转换疗法对这些患者的影响。
方法：该研究纳入了18至75岁的患者，这些患者最初被诊断为不可切除的肝细胞癌，并接受了转化治疗。完成手术后,患者接受了病理诊断，显示完全坏死。这项研究是在第一附属医院进行的回顾性研究，浙江大学医学院,从2019年1月到2021年12月。该研究的主要目标是评估总生存期和无复发生存期。
结果：共纳入60例符合纳入标准的患者。患者的中位年龄为56.6±9.5岁，其中85%是男性。1年总生存率(OS)为98.3%,三年OS为95.6%。1年无复发生存率(RFS)为81.1%,三年RFS为71.4%。在亚组分析中，BCLC0-A期和BCLCB-C期患者的RFS差异无统计学意义(p=0.296).此外,接受术后新辅助治疗的患者和未接受术后新辅助治疗的患者的RFS无统计学差异(p=0.324).
结论：转换治疗后手术切除可能是最初不可切除的肝细胞癌患者的有希望的治疗方法。预后良好，病理完全缓解。
方法：该研究纳入了18至75岁的患者，这些患者最初被诊断为不可切除的肝细胞癌，并接受了转化治疗。完成手术后,患者接受了病理诊断，显示完全坏死。这项研究是在第一附属医院进行的回顾性研究，浙江大学医学院,从2019年1月到2021年12月。该研究的主要目标是评估总生存期和无复发生存期。
结果：共纳入60例符合纳入标准的患者。患者的中位年龄为56.6±9.5岁，其中85%是男性。1年总生存率(OS)为98.3%,三年OS为95.6%。1年无复发生存率(RFS)为81.1%,三年RFS为71.4%。在亚组分析中，BCLC0-A期和BCLCB-C期患者的RFS差异无统计学意义(p=0.296).此外,接受术后新辅助治疗的患者和未接受术后新辅助治疗的患者的RFS无统计学差异(p=0.324).
结论：转换治疗后手术切除可能是最初不可切除的肝细胞癌患者的有希望的治疗方法。预后良好，病理完全缓解。
